Objectives: Previous studies have reported the expansion of CD19+Siglec-10+ B cells in systemic lupus erythematosus (SLE) patients. However, the composition of this cell population, phenotype and characteristics are still unknown.
Methods: We examined this memory B-cell subset's composition and phenotype and determined the SYK and AKT phosphorylation levels by flow cytometry. Additionally, we explored the relationship between Siglec-10 expression on B-cell subsets and clinical manifestations.
Results: Our results indicated elevated levels of Siglec-10 on naive B cells in active SLE patients. Compared with healthy controls (HCs) and inactive SLE patients, the Siglec-10+ B cells in active SLE patients exhibited elevated CD40 and CD21low levels. The levels of Siglec-10 on naive B cells were positively correlated with the proportion of CD21low double negative (DN) B cells and the SLEDAI-2K score.
Conclusions: The results indicate that the upregulation of Siglec-10+/naive B cells may function as a feedback mechanism to regulate B cell hyperreactivity. Monitoring the proportion of Siglec-10+/naive B cells may contribute to the evaluation of disease progression in SLE.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.55563/clinexprheumatol/hlnpiz | DOI Listing |
J Bras Nefrol
January 2025
Universidade Federal de São Paulo, Departamento de Medicina, São Paulo, SP, Brazil.
Collapsing glomerulopathy (CG) has a severe course typically associated with viral infections, especially HIV and parvovirus B19, systemic lupus erythematosus (SLE), among other etiologies. A 35-year-old woman with recent use of a JAK inhibitor due to rheumatoid arthritis presented with a 2-week history of fever, cervical adenopathy, and facial erythema. After admission, anemia, hypoalbuminemia, proteinuria, and severe acute kidney injury were noted.
View Article and Find Full Text PDFRheumatology (Oxford)
January 2025
The Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Objective: To explore the clinical characteristics and risk factors for adverse outcomes in patients with Sjögren's Syndrome-associated pulmonary arterial hypertension (SS-PAH).
Methods: A retrospective analysis was conducted on SS-PAH patients diagnosed by right heart catheterization (RHC) between March 2013 and March 2024 across four Chinese medical centers. Patients were categorized into primary SS-PAH (pSS-PAH) and overlap SS-PAH, based on the presence of additional autoimmune diseases.
Healthcare (Basel)
January 2025
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
This study aimed to assess patient activation using patient activation measure 13 (PAM-13) in systemic lupus erythematosus (SLE), psoriatic arthritis (PsA), and axial spondyloarthritis (axSPA). A cross-sectional study was conducted involving patients with three rheumatological conditions (SLE, PsA, and axSPA). Patients were contacted either at the clinic or through social media platforms.
View Article and Find Full Text PDFInt J Rheum Dis
January 2025
Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: Right ventricular (RV) failure is a well-recognized pivotal prognostic factor of adverse outcomes in pulmonary artery hypertension (PAH), while RV dilation provides significant implications for adaptive or maladaptive changes. PAH is a predominant cause of mortality among patients with connective tissue disease (CTD). This study aims to elucidate the prognostic significance of RV morphology, as assessed by echocardiography (ECHO), in with CTD associated with PAH (CTD-PAH).
View Article and Find Full Text PDFInt J Rheum Dis
January 2025
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Objectives: To determine the prevalence of self-reported delayed adverse events (DAEs), major AEs, and flares following COVID-19 vaccinations among patients with autoimmune rheumatic diseases (AIRDs) in Malaysia.
Methodology: An electronically validated survey from the COVID-19 vaccination in autoimmune diseases (COVAD) study group was distributed in July 2021 to patients with autoimmune diseases and healthy controls (HCs). The survey collected data on DAEs (any AE that persisted or occurred after 7 days of vaccination), any early or delayed major adverse events (MAEs), and flares following COVID-19 vaccination.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!